Reviva Pharmaceuticals - CW23 | 8-K: FY2025 Q1 EPS: USD -0.13

EPS: As of FY2025 Q1, the actual value is USD -0.13.

Financial Results for March 31, 2025

Net Loss

The company reported a net loss of approximately $6.4 million, or $0.13 per share, for the three months ended March 31, 2025, compared to a net loss of approximately $7.4 million, or $0.25 per share, for the same period in 2024.

Cash and Cash Equivalents

As of March 31, 2025, the company’s cash and cash equivalents totaled approximately $5.3 million, a decrease from approximately $13.5 million as of December 31, 2024.

Operating Expenses

Total operating expenses for the three months ended March 31, 2025, were $6.5 million, down from $7.9 million for the same period in 2024.

Research and Development Expenses

These expenses were $4.1 million for the three months ended March 31, 2025, compared to $5.8 million for the same period in 2024.

General and Administrative Expenses

These expenses were $2.4 million for the three months ended March 31, 2025, compared to $2.1 million for the same period in 2024.

Outlook / Guidance

Reviva Pharmaceuticals Holdings, Inc. anticipates the initiation of the registrational Phase 3 RECOVER-2 trial for brilaroxazine in mid-2025, subject to additional financing. The company is targeting a potential New Drug Application (NDA) submission for brilaroxazine in the fourth quarter of 2026.